Drug intelligence / Profile preview

Ezerrosu

Development stage: Unknown
Lead developer: Shinpoong Pharma
Modality: Small Molecules
Administration: Oral

Overview

Ezerrosu (also spelled Ezerosu) is a fixed-dose combination (FDC) small molecule therapy developed by Shin Poong Pharmaceutical for the treatment of hyperlipidemia. It consists of two active ingredients: ezetimibe and rosuvastatin. Ezetimibe acts by inhibiting the Niemann-Pick C1-like 1 (NPC1L1) protein in the small intestine, thereby reducing the absorption of dietary and biliary cholesterol. Rosuvastatin is a statin that competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. The combination provides a synergistic effect in lowering low-density lipoprotein cholesterol (LDL-C) and is approved for use in South Korea.

Brand names: EzerrosuEzerosu
Other names: 에제로수

Targets

NPC1L1 (Niemann-pick C1-Like 1 transporter)

Beyond the preview

Go deeper on Ezerrosu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ezerrosu.

Explore the full profile